. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: J Biomed Mater Res A. 2010 Aug;94(2):476–484. doi: 10.1002/jbm.a.32724

Table II.

Summary of ISFI Drug Release

Formulations	1 hour	1 day	1 week
Varying P85

0% P85	10.8 ± 1.7	38.2 ± 2.5	54.7 ± 3
1% P85	10.2 ± 0.6	33.6 ± 1.1	51.8 ± 1.1
2.5% P85	10.4 ± 0.5	28.2 ± 0.5^†	52.4 ± 0.4
5% P85	10.4 ± 0.4	38.4 ± 2.8	54.4 ± 1.9

Varying Mw

PLGA 2A	10.4 ± 0.5^‡	28.2 ± 0.5^‡	52.4 ± 0.4^¥
PLGA 3A	11.3 ± 1.0^Ŧ	30.0 ± 0.7^‡	71.4 ± 3.8
PLGA 4A	15.2 ± 0.7^*	47.0 ± 2.3	74.9 ± 3.8
PLGA 4.5A	21.0 ± 1.4	55.1 ± 3.1	75.6 ± 4.3
PLGA 7E	18.0 ± 0.6	51.2 ± 1.5	69.9 ± 1.3

Varying Loading

0.5% loading dose	10.6 ± 0.2	25.3 ± 2.8^§	57.4 ± 2.9^§
1% loading dose	10.4 ± 0.5	28.2 ± 0.5^§	52.4 ± 0.4^§
2% loading dose	14.2 ± 0.6	49.0 ± 2.1	76.7 ± 4.3
5% loading dose	29.9 ± 2.7^**	66.3 ± 1.3	82.5 ± 1.4

All values shown as ± Standard Error.

^†

Indicates significant difference (p<0.05) from all other varying P85 formulations

^‡

Indicates significant difference (p<0.05) from PLGA 4A, 4.5A, and 7E

^Ŧ

Indicates significant difference (p<0.05) from PLGA 4.5A, and 7E

Indicates significant difference (p<0.05) from PLGA 2A and 4.5A

^¥

Indicates significant difference (p<0.05) from all other Mw formulations

^**

Indicates significant difference (p<0.05) form all other drug loading formulations

^§

Indicates significant difference (p<0.05) from 2% and 5% drug loading